Thursday, November 04, 2021 9:26:58 PM
$HGEN new ASH abstract shows that GM-CSF receptor blocking (i.e mavrilimumab) BUT not gm-csf neutralization (Lenzilumab) significantly inhibited CART19 cell proliferation
— Jerry Q*👁️🗨️ (@ADoubleDown) November 5, 2021
Lenz > Mav (and others targeting gm-csf receptor) https://t.co/JKoTgtOBx3 pic.twitter.com/e0pow4Wtbf
new ASH abstract shows that GM-CSF receptor blocking (i.e mavrilimumab) BUT not gm-csf neutralization (Lenzilumab) significantly inhibited CART19 cell proliferation
Lenz > Mav (and others targeting gm-csf receptor)
https://ash.confex.com/ash/2021/webprogram/Paper149859.html
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM
